↓ Skip to main content

Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia not Adequately Controlled with Current Lipid-Lowering Therapy: Design and Rationale of the ODYSSEY FH…

Overview of attention for article published in Cardiovascular Drugs and Therapy, May 2014
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#35 of 717)
  • High Attention Score compared to outputs of the same age (90th percentile)
  • High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

policy
1 policy source
patent
28 patents

Citations

dimensions_citation
91 Dimensions

Readers on

mendeley
91 Mendeley
Title
Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia not Adequately Controlled with Current Lipid-Lowering Therapy: Design and Rationale of the ODYSSEY FH Studies
Published in
Cardiovascular Drugs and Therapy, May 2014
DOI 10.1007/s10557-014-6523-z
Pubmed ID
Authors

John J. P. Kastelein, Jennifer G. Robinson, Michel Farnier, Michel Krempf, Gisle Langslet, Christelle Lorenzato, Daniel A. Gipe, Marie T. Baccara-Dinet

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 91 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Netherlands 1 1%
United States 1 1%
Austria 1 1%
Unknown 88 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 20 22%
Other 11 12%
Student > Bachelor 9 10%
Student > Master 8 9%
Student > Postgraduate 6 7%
Other 20 22%
Unknown 17 19%
Readers by discipline Count As %
Medicine and Dentistry 37 41%
Agricultural and Biological Sciences 9 10%
Pharmacology, Toxicology and Pharmaceutical Science 8 9%
Biochemistry, Genetics and Molecular Biology 5 5%
Unspecified 2 2%
Other 5 5%
Unknown 25 27%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 15. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 February 2024.
All research outputs
#2,091,304
of 23,563,389 outputs
Outputs from Cardiovascular Drugs and Therapy
#35
of 717 outputs
Outputs of similar age
#21,759
of 227,951 outputs
Outputs of similar age from Cardiovascular Drugs and Therapy
#1
of 7 outputs
Altmetric has tracked 23,563,389 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 717 research outputs from this source. They receive a mean Attention Score of 4.9. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 227,951 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them